REMARKS

Any fees that may be due in connection with this application throughout its pendency may be charged to Deposit Account No. 06-1050.

IN THE SEQUENCE LISTING:

Attached herewith are two CD-ROM copies of the substitute Sequence Listing, paper copies of SEQ ID NOS: 216 and 850, and a verified statement that the content of both CD-ROMs are the same in accordance with 37 C.F.R. §§1.821-1.825.

SEQ ID NO: 216 on pages 106-107 of the Sequence Listing is amended to correct inadvertent typographical errors introduced in the sequence at amino acid positions 18, 21, 25 and 37. Amino acid 18 is amended to Histidine (His) to replace Arginine (Arg). Amino acid 21 is amended to Histidine (His) to replace Tyrosine (Tyr). Amino acid 25 is amended to Phenylalanine (Phe) to replace Tyrosine (Tyr). Amino acid 37 is amended to Proline (Pro) to replace Leucine (Leu). For reference, these changes are underlined on the paper copy of SEQ ID NO:216 provided herewith. For reference, a copy of SEQ ID NO: 850 is also provided herewith.

SEQ ID NO: 216 is described in the specification on page 6, line 4 as human growth hormone (hGH). Further, on page 94, lines 7-14, a modified hGH cytokine is described as comprising mutations at one or more amino acid residues of SEQ ID NO: 216 in positions ranging between amino acid position 56 to amino acid position 186. The point mutations result in modified hGH cytokines with amino acid sequences corresponding to SEQ ID NOS: 850 – 895. Thus, the sequence of SEQ ID NO: 216 ***should be*** 100% identical to the sequences of SEQ ID NOS: 850 - 895 ***except*** for the point mutation at the positions listed on page 94 (*i.e.* 56, 59, 64, 65, 66, 88, 92, 94, 101, 129, 130, 133, 134, 140, 143, 145, 146, 147, 183 and 186). These point mutations are also described in Figure 12F as substitutions 1 through 46. Therefore, the amendment of the four amino acids at positions 18, 21, 25 and 37 of SEQ ID NO: 216 corrects inadvertent typographical errors and does not introduce any new matter.

As further support for the amendment, many of the other cytokines and mutants described in the specification also provide a reference sequence and mutant

sequences that are 100% identical between the reference sequence and the mutant sequence except for the point mutation listed in the specification and described in the figures. For example, SEQ ID NO: 210 and mutant sequences SEQ ID NOS: 631 – 662 of G-CSF cytokine are described on page 92, lines 26-31; the sequences of SEQ ID NOS: 631-662 are 100% identical to the sequence of SEQ ID NO: 210 except for the point mutation at the positions listed.

SEQ ID NO: 978 on page 523 and SEQ ID NO: 986 on page 528 of the Sequence Listing are amended to correct inadvertent typographical errors introduced in the sequence at amino acid position 158. Amino acid 158 is amended to Glycine (Gln) to replace Proline (Pro) in each of these sequences. SEQ ID NO: 978 is a modified IFNα-2b molecule as defined in the specification on page 79, line 18. Table 2 on page 169 describes SEQ ID NO: 978 as having only one amino acid substitution at amino acid position 111. Thus, the sequence should be identical to the reference sequence at amino acid position 158. Similarly, SEQ ID NO: 986 is a modified IFNα-2b molecule and according to Table 7 on page 178 has only two amino acid substitutions; positions 111 and 125. Thus, the sequence should be identical to the reference sequence at amino acid position 158.

The computer-readable copy of the substitute Sequence Listing is titled 922SEQ.003 and both CD-ROM copies are identical to each other. The replacement Sequence Listing contains no new matter.

Entry of this amendment and examination of the application are respectfully requested.

Respectfully submitted,

Stephanie L. Seidman
Reg. No. 33,779

Address all correspondence to:

Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
E-mail: seidman@fr.com

APPENDIX

Attached herewith are:

1. Two CD-ROM copies of the Replacement Sequence Listing
2. Paper copy of SEQ ID NO: 216
3. Paper copy of SEQ ID NO: 850
4. Verified Statement Pursuant to §1.821(f)